×

Loading...
Ad by
  • 推荐 OXIO 加拿大高速网络，最低月费仅$40. 使用推荐码 RCR37MB 可获得一个月的免费服务
Ad by
  • 推荐 OXIO 加拿大高速网络，最低月费仅$40. 使用推荐码 RCR37MB 可获得一个月的免费服务

@Las Vegas

谢蓝天同学介绍名牌文章,如果有这药,我会屯点

xiaozuiba(xiaozuiba)

Discussion

This analysis of the largest randomised trial involving people vaccinated against SARS-CoV-2 infection who are at increased risk of adverse outcomes in the community and unwell with COVID-19 showed that the early addition of molnupiravir to usual care did not reduce hospital admissions or death (which were low in both treatment groups). However, participants in the molnupiravir plus usual care group recovered faster than those in the usual care group, had a higher rate of early sustained recovery, and had fewer general practitioner consultations. This faster patient-reported recovery was consistent with a reduction in detectable virus and viral load in participants who received molnupiravir compared with those who received usual care only. We did not identify any patient subgroup in which molnupiravir was associated with a reduced chance of hospital admission, and benefits in terms of time to first self-report of recovery were evenly distributed across subgroups. We recorded few serious adverse events in the trial, and none definitely related to molnupiravir.

(#15053229@0)
Last Updated: 2022-12-25
This post has been archived. It cannot be replied.
Report

Replies, comments and Discussions:

  • 枫下家园 / 医药保健 / 默克的新冠药Molnupiravir在前3个季度卖了50亿美元，然而，牛津大学最新试验发现，该药并不能降低住院率或死亡率。 -blueskygg(Grass); 2022-12-25 {568} (#15053166@0) +2
    Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.
    Full Story:
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext
    • 谢蓝天同学介绍名牌文章,如果有这药,我会屯点 -xiaozuiba(xiaozuiba); 2022-12-25 {1167} (#15053229@0) +1

      Discussion

      This analysis of the largest randomised trial involving people vaccinated against SARS-CoV-2 infection who are at increased risk of adverse outcomes in the community and unwell with COVID-19 showed that the early addition of molnupiravir to usual care did not reduce hospital admissions or death (which were low in both treatment groups). However, participants in the molnupiravir plus usual care group recovered faster than those in the usual care group, had a higher rate of early sustained recovery, and had fewer general practitioner consultations. This faster patient-reported recovery was consistent with a reduction in detectable virus and viral load in participants who received molnupiravir compared with those who received usual care only. We did not identify any patient subgroup in which molnupiravir was associated with a reduced chance of hospital admission, and benefits in terms of time to first self-report of recovery were evenly distributed across subgroups. We recorded few serious adverse events in the trial, and none definitely related to molnupiravir.

      • 当初默克可是宣布降低住院率或死亡率50%的。把有效的老药说成无效，把无效的新药说成有效，FDA和药厂一起割韭菜。 -blueskygg(Grass); 2022-12-25 {1704} (#15053252@0) +1
        At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died
        Full Story:
        https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
        • 采样对象不同,默克的受试对象至少要有1个危险因素,且年龄不明 -xiaozuiba(xiaozuiba); 2022-12-25 (#15053351@0)
          • 这么说某些人奉若神明的双盲试验也不靠谱，一个做出来降低住院率50%，另一个做出来降低0%。所以要做个试验证明IVM无效那是很容易了。 -blueskygg(Grass); 2022-12-25 (#15054084@0)
            • 对不同对象做双盲实验得到不同的结果很正常 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054622@0)
              • 所以我可以轻易设计一个双盲试验来证明辉瑞新冠药无效，找“合适”的对象，把两种药去掉一种，服用5天改3天等等，那些证明IVM无效的试验就是用的这些方法。 -blueskygg(Grass); 2022-12-26 (#15054842@0)
                • 兽药是否有效的实验做过很多,不同的结果都有人信 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054858@0)
                  • 对IVM，FDA只看无效的结果，有效的结果假装没看见。对默克药，FDA就只看厂家自己做的有效的结果，牛津大学做的无效的结果FDA是不会看见的。 -blueskygg(Grass); 2022-12-26 (#15054916@0)
                • 将所有高龄，感染超过一周并有咳嗽症状选为标的，用辉瑞实验，很容易得出，辉瑞无法阻止病人转为重症，辉瑞药物无效的结论，药物控制都是要早期介入，很重要。IVM就是这么搞掉的。 -lovedrive(深蓝爷爷); 2022-12-26 (#15054918@0)
                  • 或者找身体好症状轻的，吃不吃药都会好，就算早期介入，用药组和对照组也不会有明显区别，结论也是辉瑞药无效。 -blueskygg(Grass); 2022-12-26 (#15054984@0) +1
      • 都过去了真要屯吗 -**🐮; 2022-12-26 (#15054642@0)
        • 用默克药的105人住院，用安慰剂的只有98人住院，这药还不如安慰剂，屯它干啥？ -blueskygg(Grass); 2022-12-26 (#15054851@0) +1
        • 有就屯 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054859@0)
          • 默克这药确实没啥用，还是屯辉瑞的吧，听说辉瑞的可以免费拿了，不知道是真是假 -tzm_oasis(绿洲); 2022-12-26 (#15055008@0)
            • 满足条件的药剂师会直接给药，不用医生处方。不过这药和很多药冲突的，不能同时服用。 -blueskygg(Grass); 2022-12-26 (#15055037@0)
              • 👍 -tzm_oasis(绿洲); 2022-12-26 (#15055067@0)
    • 默克的药刚出来不久就爆出有效性不到30%，而且副作用比较大，当时的新闻到处都是。 -coolrock(coolrock); 2022-12-26 (#15055264@0)
      • FDA门槛咋这么低了？30%都批？那还不如批印度神牛的尿尿。副作用不大，正作用或许也有30%。 -bottom(核桃夹子); 2022-12-26 (#15055289@0)
      • 牛津的研究发现有效率是0。 -blueskygg(Grass); 2022-12-26 (#15055294@0)

More Topics

  • 看到枫树叶的帖子，回想一下四年前的情况，IMHO, 太荒诞了。不过，那一场，也让我悟识到不少
  • 土豆违法启动紧急状态对付反强制疫苗，
  • 新冠疫情时期发生了很多人类史上前所未有的事件，也是第一次全世界几乎所有的人都被强迫打没有经过严格监督下快速出世的疫苗。全世界专业人士还在monitor事件导致的可能的影响，为什么很多网友害怕讨论并不让大家在这里讨论？为什么呢？🤔
  • 大家探讨着疫苗的种种问题，有听医生说的，有发生在身边，有看研究论文的，并没有针对任何网友，但为什么每次总有疫苗好爱者恶狠狠地生气呢？没有人强迫你们不要打疫苗呀，要打现在还可以打呀，难道真的有后遗症这么一说？🤔
  • 请问： 有人得过耳石症吗？ 就是感觉有些头脑眩晕， 好像是老龄化的一个症状。
    • 枫下论坛主坛 /  枫下家园 /  医药保健